Royal Bank of Canada’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-79
| Closed | -$2K | – | 6403 |
|
|
2024
Q2 | $2K | Sell |
79
-11
| -12% | -$278 | ﹤0.01% | 6315 |
|
|
2024
Q1 | $4K | Sell |
90
-327
| -78% | -$14.5K | ﹤0.01% | 6038 |
|
|
2023
Q4 | $19K | Buy |
417
+226
| +118% | +$10.3K | ﹤0.01% | 5783 |
|
|
2023
Q3 | $7K | Buy |
191
+72
| +61% | +$2.64K | ﹤0.01% | 6021 |
|
|
2023
Q2 | $13K | Buy |
119
+18
| +18% | +$1.97K | ﹤0.01% | 5913 |
|
|
2023
Q1 | $29K | Sell |
101
-68
| -40% | -$19.5K | ﹤0.01% | 5493 |
|
|
2022
Q4 | $57K | Buy |
169
+122
| +260% | +$41.1K | ﹤0.01% | 5330 |
|
|
2022
Q3 | $9K | Buy |
47
+4
| +9% | +$766 | ﹤0.01% | 5973 |
|
|
2022
Q2 | $9K | Sell |
43
-25
| -37% | -$5.23K | ﹤0.01% | 5951 |
|
|
2022
Q1 | $22K | Sell |
68
-167
| -71% | -$54K | ﹤0.01% | 6061 |
|
|
2021
Q4 | $76K | Sell |
235
-180
| -43% | -$58.2K | ﹤0.01% | 5590 |
|
|
2021
Q3 | $202K | Buy |
415
+41
| +11% | +$20K | ﹤0.01% | 4661 |
|
|
2021
Q2 | $174K | Sell |
374
-89
| -19% | -$41.4K | ﹤0.01% | 4724 |
|
|
2021
Q1 | $320K | Buy |
463
+105
| +29% | +$72.6K | ﹤0.01% | 4095 |
|
|
2020
Q4 | $265K | Buy |
358
+179
| +100% | +$133K | ﹤0.01% | 4129 |
|
|
2020
Q3 | $124K | Buy |
179
+100
| +127% | +$69.3K | ﹤0.01% | 4385 |
|
|
2020
Q2 | $67K | Buy |
79
+76
| +2,533% | +$64.5K | ﹤0.01% | 4609 |
|
|
2020
Q1 | $1K | Sell |
3
-23
| -88% | -$7.67K | ﹤0.01% | 5897 |
|
|
2019
Q4 | $6K | Buy |
+26
| New | +$6K | ﹤0.01% | 5683 |
|
|
2019
Q3 | – | Sell |
-6
| Closed | -$1K | – | 5991 |
|
|
2019
Q2 | $1K | Buy |
+6
| New | +$1K | ﹤0.01% | 5711 |
|
|
2018
Q4 | – | Sell |
-1
| Closed | – | – | 5815 |
|
|
2018
Q3 | $0 | Buy |
+1
| New | – | ﹤0.01% | 6097 |
|
|
2018
Q2 | – | Sell |
-150
| Closed | -$25K | – | 5913 |
|
|
2018
Q1 | $25K | Buy |
+150
| New | +$25K | ﹤0.01% | 4759 |
|